At a glance
- Originator Unknown
- Developer BTG
- Class Anxiolytics; Nootropics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 03 Feb 1997 No-Development-Reported for Anxiety disorders in United Kingdom (PO)